摘要
目的观察经皮冠状动脉介入治疗（PCI）前应用β-受体阻滞剂是否可减少介入并发症的发生。方法行PCI病人210例,随机分为β-受体阻滞剂组（105例）及对照组（105例）。分别于术前、术后6～8 h及16～24 h抽取血标本检测心肌肌酸激酶（CK-MB）、肌钙蛋白T（TnT）、肾上腺素（E）、去甲肾上腺素（NE）水平,并随访病人院内、院外1年心脏事件的发生率。结果PCI术后,两组CK-MB及TnT水平均有所升高,TnT升高幅度较明显。PCI术后16～24 h,β-受体阻滞剂组TnT的升高幅度较对照组低,差异有统计学意义（t=2.237,P〈0.05）。β-受体阻滞剂组并发症发生率较对照组低,差异有统计学意义（2χ=5.34,P〈0.05）。院内病死率及1年随诊病死率较低。结论PCI治疗前应用β-受体阻滞剂可减少介入并发症的发生。
Objective To observe the effect of pretreatment of β-adrenergic blocker on the occurrence of complications of percutaneous coronary interventional therapy （PCI）. Methods This study included 105 patients undergoing PCI pre-treated with β-adrenergic blocker, and 105 without β- adrenergic blocker served as control. CK-MB, E. NE were tested before and 6--8 h,16-- 24 h after PCI. Occurrence of PCI complications during hospitalization and after one year were analyzed. Results There are not significant difference between the two groups on CK ME. E. NE. The occurrence of PCI complications was found lower in β-adren ergic blocker treated patients than in control group （X^2 = 5.31, P〈0.05）. Conclusion Pretreatment with β-adrenergic blocker can reduce the occurrence of PCI complications.
出处
《青岛大学医学院学报》
CAS
2008年第4期309-311,共3页
Acta Academiae Medicinae Qingdao Universitatis
基金
山东省卫生厅青年基金资助项目(2001CA2CBB5)
